NDx is excited to announce our contribution to Lilly's ALZ 2 Trailblazer trial, which began in July 2020. We've been working with patients in this trial and have enrolled 39 patients, out of the total of over 1700 enrolled since the start of the trial!
We are proud to report that the trial has yielded promising results, with Lilly's investigational therapy donanemab showing a significant slowing of cognitive and functional decline in early symptomatic Alzheimer's disease. The results of the study have been highly statistically significant, with donanemab treatment showing a 35% slowing of clinical decline compared to placebo. Additionally, participants on donanemab experienced a 40% less decline in the ability to perform daily activities.
At NDx, we are honored to have been selected for this study and to have contributed to this groundbreaking research. We believe that the highly statistically significant clinical benefits observed in this study show the potential for a much-needed treatment option for those living with Alzheimer's disease.
Our team of highly trained neurologists and staff at NDx are committed to providing top-quality care for all of our patients. We are excited to continue contributing to the advancement of neurological research and providing cutting-edge diagnostics and treatments to our patients.
We would like to extend our sincere gratitude to all of the participants and their loved ones who have dedicated their time and energy to this study. We are humbled and grateful to be a part of this important work and look forward to continuing to make a positive impact on the lives of those living with neurological conditions.
